Etiologies of diabetic nephropathy are largely unknown. Recent investigations have shed light on the potent roles of growth factors in the development of diabetic nephropathy.
expression. The expressions of VEGF-A and Ang-2 were increased both at mRNA and protein levels in the diabetic glomeruli. Ang-2 protein was also detected in the urine from diabetic animals but not from the controls. Conversely, the expression of Ang-1 was decreased in diabetic glomeruli. High glucose up-regulated VEGF-A mRNA and Ang-2 mRNA expression and down-regulated affects approximately one-third of all diabetic patients and is a major cause of morbidity and mortality due to both type 1 and type 2 diabetes 1, 2 . This complication has also become the leading cause of end-stage renal disease (ESRD) all over the world. Prevention and treatment of chronic renal insufficiency would require the application of therapies that specifically interfere with the pathogenesis of diabetic nephropathy. However, the molecular mechanisms involved in diabetic nephropathy are largely unknown.
Recently, the involvement of various growth factors and cytokines, including VEGF 3 , angiotensin II 4 , insulin-like growth factor-I 5 , monocyte chemoattractant protein-1 6 and transforming growth factor-β 1 7 , has been reported in the development of diabetic nephropathy.
VEGF is considered a powerful angiogenic and permeability-inducing factor and is known to exert its effects via VEGF receptors 8 . The levels of VEGF expression seem to be critical: reduction or increase in these levels may lead to glomerulopathy with lesions resembling those seen in preeclampsia or HIV-associated nephropathy 9 . Podocytes also secrete Ang-1, which acts via the endothelial Tie-2 receptor 10 . The
Ang-1-Tie-2 signaling loop is essential for vessel maturation and stabilization 11 .
Ang-1 is also unique in its ability to reduce endothelial cell permeability 12 and probably modulates some of the effects of VEGF 13 .
Ang-2 is an antagonistic ligand for Tie-2 in endothelial cells 14 that inhibits the binding of Ang-1 to Tie-2, and thereby the Ang-1-induced Tie-2 phosphorylation.
Endothelial cells of transgenic mice overexpressing Ang-2 have a phenotype similar to those of Ang-1-deficient mice 15 .
In this study, we conducted both in vivo and in vitro experiments to examine the glomerular expression of VEGF-A, Ang-1, and Ang-2 under diabetic conditions and the effects of those growth factors on the glomerular endothelial cell gene expression.
METHODS

Reagents
The following reagents were used in this study: recombinant human VEGF 
Animals and induction of diabetes
Eight-week-old, male, C57/Bl6J mice were induced diabetes by intraperitoneal injection of streptozotocin (STZ; Sigma Aldrich, St. Louis, MO, USA) freshly dissolved in an ice-cold citrate buffer at a dose of 100 mg/kg once a day for 3 days.
All the experiments in this study were performed in accordance with the Guidelines of the Animal Care and Use of Chiba University, Japan. Mice urine immunosorbent assay (ELISA) kit (Albuwell M; Exocell, Philadelphia, PA, USA).
Isolation of glomeruli
Isolation of mice glomeruli was performed as described previously 16 . Kidneys were frozen in optimal cryotomy temperature (OCT) compound and sectioned into 8-µm-thick slices. Immunohistochemistry was performed as described previously 17 .
Cell culture
Real-time reverse-transcriptase polymerase chain reaction
The mRNA expression in glomeruli or podocytes was analyzed by real-time polymerase chain reaction (PCR) as described previously 18 . M32599, 757-855bp), which was amplified using the primers,
5′-TGTGTCCGTCGTGGATCTGA-3′ and
Western blotting
Western blotting was performed exactly as described in a previous report 19 . The medium harvested from podocyte was concentrated to about 4-fold by using the Centricon YM-10 filter (Cat. No 4205, Millipore, Billerica, MA, USA) according to the manufacturer's instructions.
Statistical analysis
The statistical analysis of the results was performed by the unpaired Student t test.
P values < 0.05 were considered significant.
RESULTS
Alteration of the glomerular expression of VEGF-A, Ang-1, and Ang-2 under diabetic conditions
To examine the expression of angiogenesis-related factors during the early stages of the pathogenesis of diabetic glomerulopathy, STZ-induced diabetic mice as well as control mice were divided into 4 groups: mice not injected, those at 2 weeks after injection, those at 4 weeks after injection, and those at 8 weeks after
injection. Blood and urine samples were obtained from each group at each time point, and the glomeruli were isolated from renal samples and analyzed for gene and protein expressions. Fasting plasma glucose levels in mice with STZ-induced diabetes were twice those in nondiabetic control mice ( Figure 1A) . A significant increase was noted in the urinary albumin excretion in diabetic mice at 2 weeks after the STZ injection ( Figure 1B ). The expression of VEGF-A mRNA in the diabetic mice was significantly higher (by 220%) than that in the non-diabetic control mice (Figure 2A ). Ang-2 mRNA expression also increased by 140 and 340% in the diabetic mice from 4 weeks after STZ injection, respectively ( Figure   2B ). Conversely, mRNA expression level of Ang-1 was significantly lower in the diabetic mice than in non-diabetic control mice at 8 weeks after injection ( Figure   2C ). There was no significant difference in the glomerular expression level of Tie-2 mRNA between the diabetic and control mice ( Figure 2D ). Western blot analysis confirmed that glomerular expression of Ang-2 protein in diabetic mice was 1.5-fold that in nondiabetic mice ( Figure 2E , right). Ang-2 protein was also detected in the urine samples of diabetic mice, but not in those of control animals ( Figure 2E, left) . The increased glomerular expression of VEGF-A protein in diabetic mice was also confirmed by immunohistochemistry, as shown in Figure   2F . We would like to emphasize that the gene and protein expressions in this study were examined using isolated glomeruli with 97% purity, rather that the renal cortex, which was used in previous studies. Ang-1 is also known to be expressed in vascular smooth muscle cells in the kidney 10 ; therefore, our approach is would be more direct and accurate in assessing glomerular expressions of genes and proteins.
Notably, we could also detect Ang-2 proteins in the urine samples obtained from diabetic animals, as shown in Figure 2E . On the basis of a previous study that indicated that Ang-2 mRNA and protein are barely detected in healthy, mature glomeruli 24 , we can infer that urinary Ang-2 levels can be used as an early marker of diabetic nephropathy in the future.
There is increasing evidence indicating the role of podocytes in the development of diabetic nephropathy 25 . Therefore, we used cultured renal podocytes to examine the effect of high glucose concentrations on the expressions of VEGF-A, Ang-1, and Ang-2 in these cells. Exposure to high glucose concentrations lead to up-regulation of VEGF mRNA and protein expression in podocytes via activation of the α and βII isoforms of protein kinase C (PKC) and extracellular signal-regulated kinases (ERKs) 26 . However, to our knowledge, this is the first report showing that exposure to high glucose concentrations increases the Ang-2 mRNA expression and decreases Ang-1 mRNA expression in podocytes, although the exact mechanism underling this alteration in the expression patterns of Ang-1 and Ang-2 remains unclear.
Ang-1 has been reported to act as an anti-permeability and anti-inflammatory agent in vitro 27 . Our data indicated that Ang-1 attenuated VEGF-A-mediated overexpression of VCAM-1 and PDGF-B in cultured glomerular endothelial cells (Fig.4) . 
